Skip to main content
. 2021 Jan 20;6:26. doi: 10.1038/s41392-020-00448-5

Fig. 2.

Fig. 2

Presupposition analysis of the clinical activity of Neo-DCVac in the treatment of advanced lung cancer. a Clinical event timeline for the 12 patients who received Neo-DCVac treatment, from biopsy until the time of death due to progressive disease (PD) or last follow-up time. b Progression-free survival (PFS) of patients treated with Neo-DCVac. c Overall survival (OS) of patients treated with Neo-DCVac. d Best observed response for 12 patients given Neo-DCVac with or without ICI treatment. e PFS of patients treated with Neo-DCVac or Neo-DCVac and ICIs. f OS of patients treated with Neo-DCVac or Neo-DCVac and ICIs